BRAF and cancer: In Australia, there is currently access to vemurafenib/cobimetinib for adult patients with BRAF-mutant cancers via a national clinical trial platform called the Molecular Screening and Therapeutics Program (MoST): Addendum 12, Substudies 27-30 (ACTRN12620000861954).